Boston Scientific’s TriVascular Stake Gives AAA Market New Entrant
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific's investment in abdominal aortic aneurysm device developer TriVascular, Inc., with an option to buy, shows the company is following through on its promise to become a significant player in the potentially lucrative AAA market
You may also be interested in...
Enovus AAA Endograft Seal Of Approval Sought For Novel O-Ring Design
TriVascular's low-profile Enovus could prove an attractive endograft option for women and other patients with small arteries, if the novel design proves safe and effective
Enovus AAA Endograft Seal Of Approval Sought For Novel O-Ring Design
TriVascular's low-profile Enovus could prove an attractive endograft option for women and other patients with small arteries, if the novel design proves safe and effective
U.S. AAA Stent Graft Market Reaching Capacity As Larger Players Weigh In
Abdominal aortic aneurysm (AAA) stent graft technology ranks high on the research agendas of several manufacturers this year, with a wave of first and next-generation product launches anticipated